UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome

Surgery, 2012-05, Vol.151 (5), p.710-716

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers

Journal of clinical oncology, 2010-10, Vol.28 (28), p.4316-4323

2010

Link zum Volltext

Verfügbarkeit prüfen

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5983-5992

2005

Link zum Volltext

Verfügbarkeit prüfen

Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes

Journal of clinical oncology, 2009-01, Vol.27 (2), p.220-226

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer

Journal of clinical oncology, 2012-03, Vol.30 (9), p.930-935

2012

Link zum Volltext

Verfügbarkeit prüfen

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

Radiation oncology (London, England), 2013-01, Vol.8 (1), p.13-13, Article 13

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

Cancer chemotherapy and pharmacology, 2013, Vol.71 (1), p.63-72

2013

Link zum Volltext

Verfügbarkeit prüfen

Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases

Journal of magnetic resonance imaging, 2009-05, Vol.29 (5), p.1154-1162

2009

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy

Annals of surgical oncology, 2006-11, Vol.13 (11), p.1443-1449

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC)

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.TPS42-TPS42

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.TPS541-TPS541

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS5090-TPS5090

2017

Link zum Volltext

Verfügbarkeit prüfen

Retrospective analysis of toxicity in patients (pts) with liver metastases (mets) from phase 3 studies of trastuzumab emtansine (T-DM1) in pts with metastatic breast cancer (MBC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.609-609

2014

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant chemotherapy for breast cancer

Langenbeck's archives of surgery, 2002-07, Vol.387 (3-4), p.109-116

2002

Link zum Volltext

Verfügbarkeit prüfen

Racial/ethnic (RE) differences in the occurrence of HER2 and hormone receptor (HR)-defined breast cancer (BC) in California (CA)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.634-634

2014

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy

Breast disease, 2004, Vol.21, p.23

2004

Link zum Volltext

Verfügbarkeit prüfen

Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.527-527

2012

Link zum Volltext

Verfügbarkeit prüfen

Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy prior to surgery define outcome

Surgery, 2012-01, Vol.151 (5), p.710-716

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of exemestane in combination with metformin and rosiglitazone in non-diabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

Cancer chemotherapy and pharmacology, 2012-09, Vol.71 (1), p.63-72

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(77)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome

Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes

Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer

Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases

Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy

Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC)

Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC)

A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Retrospective analysis of toxicity in patients (pts) with liver metastases (mets) from phase 3 studies of trastuzumab emtansine (T-DM1) in pts with metastatic breast cancer (MBC)

Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study

Adjuvant chemotherapy for breast cancer

Racial/ethnic (RE) differences in the occurrence of HER2 and hormone receptor (HR)-defined breast cancer (BC) in California (CA)

Neoadjuvant chemotherapy

Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting

Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy prior to surgery define outcome

Phase I trial of exemestane in combination with metformin and rosiglitazone in non-diabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

Suchergebnisse filtern